307 related articles for article (PubMed ID: 32545704)
1. Management of Drug Resistance in Mantle Cell Lymphoma.
Roué G; Sola B
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545704
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells.
Bogner C; Ringshausen I; Schneller F; Fend F; Quintanilla-Martinez L; Häcker G; Goetze K; Oostendorp R; Peschel C; Decker T
Br J Haematol; 2003 Jul; 122(2):260-8. PubMed ID: 12846895
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma.
Saleh K; Cheminant M; Chiron D; Burroni B; Ribrag V; Sarkozy C
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804999
[TBL] [Abstract][Full Text] [Related]
4. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
[TBL] [Abstract][Full Text] [Related]
6. Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Martin P; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2019 Aug; 60(8):1853-1865. PubMed ID: 30696305
[TBL] [Abstract][Full Text] [Related]
7. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Bogner C; Peschel C; Decker T
Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
[TBL] [Abstract][Full Text] [Related]
8. A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress.
Ben Younes K; Body S; Costé É; Viailly PJ; Miloudi H; Coudre C; Jardin F; Ben Aissa-Fennira F; Sola B
BMC Cancer; 2017 Aug; 17(1):538. PubMed ID: 28797244
[TBL] [Abstract][Full Text] [Related]
9. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
10. Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma.
Beà S; Amador V
Curr Oncol Rep; 2017 Jun; 19(6):43. PubMed ID: 28466437
[TBL] [Abstract][Full Text] [Related]
11. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Kluin-Nelemans HC; Beà S; Hartmann E; Salaverria I; Hutter G; Perez-Galan P; Roue G; Pott C; Le Gouill S; Cortelazzo S; Rule S; Hess G; Zaja F; Vitolo U; Szymczyk M; Walewski J; Ribrag V; Unterhalt M; Hermine O; Hoster E;
Leuk Lymphoma; 2011 Dec; 52(12):2226-36. PubMed ID: 21851218
[TBL] [Abstract][Full Text] [Related]
12. Update on the molecular pathogenesis and targeted approaches of mantle cell lymphoma: summary of the 12th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Amador V; Callanan M; Jerkeman M; Le Gouill S; Pott C; Rule S; Zaja F;
Leuk Lymphoma; 2015 Apr; 56(4):866-76. PubMed ID: 25015778
[TBL] [Abstract][Full Text] [Related]
13. Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference.
Dreyling M; Hoster E; Bea S; Hartmann E; Horn H; Hutter G; Salaverria I; Pott C; Trneny M; Le Gouill S; Cortelazzo S; Szymczyk M; Jurczak W; Shpilberg O; Ribrag V; Hermine O;
Leuk Lymphoma; 2010 Sep; 51(9):1612-22. PubMed ID: 20629519
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging treatment options for mantle cell lymphoma.
Fakhri B; Kahl B
Ther Adv Hematol; 2017 Aug; 8(8):223-234. PubMed ID: 28811872
[TBL] [Abstract][Full Text] [Related]
15. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
16. A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.
Kurita D; Takeuchi K; Kobayashi S; Hojo A; Uchino Y; Sakagami M; Ohtake S; Takahashi H; Miura K; Iriyama N; Sugitani M; Miyoshi H; Hatta Y; Ohshima K; Takei M
Virchows Arch; 2016 Oct; 469(4):471-6. PubMed ID: 27457074
[TBL] [Abstract][Full Text] [Related]
17. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
18. NF-κB signaling and its relevance to the treatment of mantle cell lymphoma.
Balaji S; Ahmed M; Lorence E; Yan F; Nomie K; Wang M
J Hematol Oncol; 2018 Jun; 11(1):83. PubMed ID: 29907126
[TBL] [Abstract][Full Text] [Related]
19. Turning Point in the Treatment of Mantle Cell Lymphoma.
Motokura T
Yonago Acta Med; 2019 Mar; 62(1):1-7. PubMed ID: 30962738
[TBL] [Abstract][Full Text] [Related]
20. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network.
Dreyling M; Kluin-Nelemans HC; Beà S; Klapper W; Vogt N; Delfau-Larue MH; Hutter G; Cheah C; Chiappella A; Cortelazzo S; Pott C; Hess G; Visco C; Vitolo U; Klener P; Aurer I; Unterhalt M; Ribrag V; Hoster E; Hermine O;
Leuk Lymphoma; 2013 Apr; 54(4):699-707. PubMed ID: 23020649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
